drugset
drugset / Trial / NCT05328583

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects

NCT05328583 ↗

Phase 1 Unknown 64 enrolled RetroLead (Shanghai) BioPharma Co., Ltd.
RandomizedParallel-groupTriple-blindOther

Summary

This is a randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending dose (Part A) and multiple ascending dose (Part B) of HRS5685 tablet in healthy subjects.

Timeline

Start
2022-04-15
Primary completion
2023-03-10
Completion
2023-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS5685 Unknown — Oral

Indications

HIV infectious disease